Derived from a young human female, the NCI-H292 cell line
comes from the mucoepidermoid pulmonary carcinoma of a metastasized lung cancer
found in the lymph node. The cell line has been used for viral research and
related drug development tied to infection by the herpes simplex, mumps, and
measles viruses. With an epithelial morphology, NCI-H292 cells are easy to grow
in culture and modify genetically using optimized transfection
reagents. Therapies relying on gene-silencing via siRNA transfection or the
introduction of important protein sequences into cells can be tested quickly
and efficiently in the cell line, granting quick and reliable results.
The NCI-H292 cell line was established from the lymph node metastasis lung cells derived from a female patient suffering from mucoepidermoid pulmonary carcinoma (lung cancer). The cells exhibit an epithelial morphology, test negative for L-DOPA decarboxylase and ultimately demonstrate similar characteristics as non-carcinogenic cells do. The NCI-H292 cells have shown susceptibility to the Hepatitis B virus, making it a useful biomedical research model. Altogen Biosystems manufactures a high efficiency transfection reagent to further examine the properties of the NCI-H292 cell line for lung cancer treatments. Transfection Reagent for NCI-H292 Cells (Lung Carcinoma Cells, CRL-1848)
Comments
Post a Comment